Market Mover | ResMed Shares Rise Nearly 6% on Profit Beat
Market Mover | ResMed Shares Rise Nearly 6% on Profit Beat
Gross Shares of $ResMed Inc (RMD.AU)$ rose 5.81% to A$37.69 on Friday, following the release of ResMed's first-quarter results for the fiscal year 2025. The medical equipment manufacturer not only met but exceeded Wall Street's estimates for quarterly profit.
股票$ResMed Inc (RMD.AU)$ 周五，随着瑞思迈发布2025财年第一季度业绩，股价上涨5.81%至A$37.69。这家医疗设备制造商不仅达到了华尔街对季度利润的预期，而且超出了。
First Quarter 2025 Highlights
2025财年第一季度亮点
Revenue increased by 11% yoy, from $1.1 billion to $1.2 billion.
Gross margin improved 420 bps yoy, from from 54.4% to 58.6%.
Income from operations increased 34% yoy, from $289 million to $387.3 million.
Diluted earnings per share grew 42% from $1.49 to $2.11.
营业收入同比增长11%，从$11亿增至$12亿。
毛利率同比增长420个基点，从54.4%提高至58.6%。
营运利润同比增长34%，从$28900万增至$38730万。
每股摊薄收益增长42%，从$1.49增至$2.11。
The robust revenue growth in the quarter is fueled by higher demand for its sleep devices and masks portfolio, along with a surge in its residential care software business. ResMed's improved gross margin is credited to enhanced manufacturing efficiency, reduced component costs, and higher average selling prices. This month, ResMed launched its '2030 strategy', aiming to empower over 500 million individuals to reach their full health potential by 2030.
本季度营业收入强劲增长，来自对其睡眠设备和口罩组合的更高需求，以及住宅护理软件业务的激增。瑞思迈改善的毛利率归功于增强的制造效率，降低的零部件成本和更高的平均销售价格。本月，瑞思迈推出了其“2030年战略”，旨在到2030年赋予超过50000万个体达到其全面健康潜力。
According to the Chairman and CEO of ResMed,
根据瑞思迈的董事长兼首席执行官，
"Our first-quarter fiscal year 2025 results reflect ongoing momentum and strong execution across all areas of our business. As we celebrate 35 years of growth and innovation, our recently launched 2030 strategy will further enable us to transform sleep health, breathing health, and healthcare technology at home. "
“我们2025财年第一季度的业绩反映了持续的势头和在业务的所有领域的强劲执行。在庆祝成立35周年的同时，我们最近推出的2030战略将进一步使我们能够在家中改变睡眠健康、呼吸健康和医疗科技。”
Sources: Reuters, ResMed
来源：路透社，瑞思迈
